Beta
Cangrelor
medication Under reviewCangrelor is an intravenous, fast-acting P2Y12 receptor antagonist used as an antiplatelet agent, primarily in the setting of percutaneous coronary intervention (PCI). It is a non-thienopyridine ATP analog that reversibly blocks the P2Y12 receptor on platelets, preventing ADP-mediated platelet activation and aggregation. Because it is given intravenously and has a very short half-life, cangrelor provides rapid onset and offset of platelet inhibition. Mechanistically, cangrelor binds directly and reversibly to the P2Y12 receptor, leading to near-immediate inhibition of platelet function within minutes of starting the infusion. Its effects dissipate quickly, with platelet function returning toward normal within about an hour after discontinuation, which makes it useful when strong but controllable platelet inhibition is required around invasive procedures. In clinical practice, it is used as adjunctive therapy during PCI, and as a bridging agent when oral P2Y12 inhibitors must be interrupted before surgery. From a general health perspective, cangrelor is not a lifestyle supplement but a hospital-based, prescription-only drug reserved for high-risk cardiovascular interventions. Its main application is to reduce acute thrombotic complications such as myocardial infarction and stent thrombosis around PCI, while allowing clinicians to better manage bleeding risk due to its rapid reversibility. It is not appropriate for self-directed use in healthy individuals outside of carefully supervised clinical or research settings.
Research summary
Human research on cangrelor centers almost entirely on patients undergoing PCI or requiring short-term bridging of antiplatelet therapy, rather than on healthy volunteers in the general population. Large randomized controlled trials and meta-analyses have demonstrated that cangrelor reduces ischemic events such as periprocedural myocardial infarction and stent thrombosis, with only a modest increase in non–life-threatening bleeding and no significant increase in severe or intracranial bleeding in these controlled settings. Across these studies, the evidence base is considered strong for its role as an adjunctive antiplatelet therapy in PCI. Data in typical healthy individuals without cardiovascular disease are limited to the inclusion of generally stable elective PCI populations rather than truly healthy volunteers, and no research supports use for broader health optimization. The consensus is that cangrelor is an effective, rapidly reversible antiplatelet drug for specific interventional cardiology indications, with bleeding risk that is manageable when used according to established protocols.
Reported Benefits
No reports yet
Be the first to report this effect and help the community.
Add Cangrelor to your stack to report effects
Real-World Study Examines Cangrelor Dosing for Antiplatelet Bridging After PCI
Schaefer A, et al.
Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives
Angiolillo DJ, Rollini F, Franchi F, et al.
Optimizing the Use of Cangrelor in the Real World.
Angiolillo DJ, Firstenberg MS, Price MJ
Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention
Bhatt DL, Stone GW, Mahaffey KW, et al.
No reports yet
Be the first to report this effect and help the community.
Add Cangrelor to your stack to report effects
Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives
Angiolillo DJ, Rollini F, Franchi F, et al.
Optimizing the Use of Cangrelor in the Real World.
Angiolillo DJ, Firstenberg MS, Price MJ
Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention
Bhatt DL, Stone GW, Mahaffey KW, et al.
No reports yet
Be the first to report this effect and help the community.
Add Cangrelor to your stack to report effects
Real-World Study Examines Cangrelor Dosing for Antiplatelet Bridging After PCI
Schaefer A, et al.
Reported Side Effects
No reports yet
Be the first to report this effect and help the community.
Add Cangrelor to your stack to report effects
Real-World Study Examines Cangrelor Dosing for Antiplatelet Bridging After PCI
Schaefer A, et al.
Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives
Angiolillo DJ, Rollini F, Franchi F, et al.
Related health conditions
Research showing how this habit affects specific health conditions. Always consult healthcare professionals.
May Help With
Coronary artery disease or other cardiac conditions
Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives
Angiolillo DJ, Rollini F, Franchi F, et al.
Optimizing the Use of Cangrelor in the Real World.
Angiolillo DJ, Firstenberg MS, Price MJ
Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention
Bhatt DL, Stone GW, Mahaffey KW, et al.
Elevated LDL cholesterol or total cholesterol levels
Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives
Angiolillo DJ, Rollini F, Franchi F, et al.
Research (4 studies)
Real-World Study Examines Cangrelor Dosing for Antiplatelet Bridging After PCI
Schaefer A, et al.
Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives
Angiolillo DJ, Rollini F, Franchi F, et al.
Optimizing the Use of Cangrelor in the Real World.
Angiolillo DJ, Firstenberg MS, Price MJ
Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention
Bhatt DL, Stone GW, Mahaffey KW, et al.
Community updates
No updates yet for this supplement.
Be the first to share your experience!